Transglutaminase 2 as a therapeutic target for neurological conditions
| Autor: | Gail V.W. Johnson, Jeffrey W. Keillor |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Parkinson's disease
Tissue transglutaminase Clinical Biochemistry Context (language use) Disease Bioinformatics 03 medical and health sciences 0302 clinical medicine Huntington's disease GTP-Binding Proteins Drug Discovery medicine Humans Trauma Nervous System Protein Glutamine gamma Glutamyltransferase 2 030304 developmental biology Pharmacology 0303 health sciences Transglutaminases biology Mechanism (biology) business.industry Multiple sclerosis Neurodegenerative Diseases medicine.disease 3. Good health Cns injury biology.protein Molecular Medicine business 030217 neurology & neurosurgery |
| Zdroj: | Expert Opinion on Therapeutic Targets. 25:721-731 |
| ISSN: | 1744-7631 1472-8222 |
| Popis: | Introduction : Transglutaminase 2 (TG2) has been implicated in numerous neurological conditions, including neurodegenerative diseases, multiple sclerosis, and CNS injury. Early studies on the role of TG2 in neurodegenerative conditions focused on its ability to "crosslink" proteins into insoluble aggregates. However, more recent studies have suggested that this is unlikely to be the primary mechanism by which TG2 contributes to the pathogenic processes. Although the specific mechanisms by which TG2 is involved in neurological conditions have not been clearly defined, TG2 regulates numerous cellular processes through which it could contribute to a specific disease. Given the fact that TG2 is a stress-induced gene and elevated in disease or injury conditions, TG2 inhibitors may be useful neurotherapeutics. Areas covered Overview of TG2 and different TG2 inhibitors. A brief review of TG2 in neurodegenerative diseases, multiple sclerosis and CNS injury and inhibitors that have been tested in different models. Database search: https://pubmed.ncbi.nlm.nih.gov prior to July 1, 2021. Expert opinion : Currently, it appears unlikely that inhibiting TG2 in the context of neurodegenerative diseases would be therapeutically advantageous. However, for multiple sclerosis and CNS injuries, TG2 inhibitors may have the potential to be therapeutically useful and thus there is rationale for their further development. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|